EU indices slightly down | TA focus on GlaxoSmithKline


European stocks report | GlaxoSmithKline | Airbus | EssilorLuxottica | Julius Baer...

Downtrend 5

Friday, European stocks ended mixed. The Stoxx Europe 600 Index added 0.16%. Germany's DAX 30 gained 0.35%, the U.K.'s FTSE 100 rose 0.63%, while France's CAC 40 was down 0.31%.

45% of STOXX 600 constituents traded higher Friday.
70% of the shares trade above their 20D MA vs 71% Thursday (above the 20D moving average).
49% of the shares trade above their 200D MA vs 48% Thursday (above the 20D moving average).

The Euro Stoxx 50 Volatility index eased 1.23pt to 25.58, a new 52w high.

3mths relative high: Chemicals, Utilities
3mths relative low: Retail, Real Estate

Europe Best 3 sectors
automobiles & parts, basic resources, technology

Europe worst 3 sectors
travel & leisure, insurance, energy

The 10yr Bund yield fell 2bps to -0.47% (below its 20D MA). The 2yr-10yr yield spread rose 0bp to -22bps (above its 20D MA).

GE 07:00: Jun PPI YoY, exp.: -2.2%
GE 07:00: Jun PPI MoM, exp.: -0.4%
EC 09:00: May Current Account, exp.: E10.2B
FR 14:00: 12-Mth BTF auction, exp.: -0.56%
FR 14:00: 3-Mth BTF auction, exp.: -0.56%
FR 14:00: 6-Mth BTF auction, exp.: -0.55%

In Asian trading hours, EUR/USD eased to 1.1419 and GBP/USD slid to 1.2525. USD/JPY rebounded to 107.38. This morning, government data showed that Japan's exports declined 26.2% on year in June (-24.7% expected) and imports slid 14.4% (-17.6% expected).

Spot gold retreated to $1,807 an ounce.

GlaxoSmithKline, a pharmaceutical group, said it has signed a strategic collaboration agreement with biotechnology company CureVac for the development and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The company added: "GSK will make an equity investment in CureVac of £130m (E150m), representing close to a 10% stake, an upfront cash payment of £104m (E120m) and a one-time reimbursable payment of £26m (E30m) for manufacturing capacity reservation, upon certification of CureVac's commercial scale manufacturing facility currently under construction in Germany." From a chartist point of view, prices remain stuck within a mid term consolidation channel. The stock price is challenging its 20 and 50 DMAs. The RSI stands above 50% but lacks momentum. Above 1561p, the bias remains bullish. Next resistance thresholds are set at 1749p and 1857p in extension. A break below 1561p would call for a reversal down trend towards 1490p and 1415p.

Source: GAIN Capital, TradingView

Marks & Spencer, a retailing group, will announce hundreds of job cut this week due to the Covid-19, reported Sky News citing people familiar with the matter.

SSE, an energy company, was downgraded to "hold" from "buy" at Societe Generale.

Standard Life Aberdeen, an investment company, was downgraded to "underweight" from "equalweight" at Barclays.

Airbus, an aircraft manufacturer, said it has secured a 500 million pounds contract from the U.K. Ministry of Defence to build an additional satellite to support British military communications until at least 2040.

Natixis', a banking group, owner BPCE said it has no plan to acquire the remaining shares in the company, reported Bloomberg citing an emailed statement.

EssilorLuxottica, an eyewear conglomerate, announced that it has initiated legal proceedings before a Dutch district court to "obtain information from GrandVision. This is to assess the way GrandVision has managed the course of its business during the COVID-19 crisis, as well as the extent to which GrandVision has breached its obligations under the support agreement".

Teleperformance, an omnichannel company, was upgraded to "overweight" from "equalweight" at Morgan Stanley.

Intesa Sanpaolo, an Italian banking group, announced that it has raised is takeover offer for UBI Banca by adding an extra cash portion of 0.57 euro per share, representing about 652 million euros.

Julius Baer, a Swiss private bank, reported that 1H net income rose 43.2% on year to 491 million Swiss franc and operating income grew 8.9% to 1.85 billion Swiss franc. Also, assets under management fell 5.7% to 402 billion Swiss franc.

Enel: E0.168

More from Equities

Disclaimer: The information on this web site is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement. The information and opinions in this report are for general information use only and are not intended as an offer or solicitation with respect to the purchase or sale of any currency or CFD contract. All opinions and information contained in this report are subject to change without notice. This report has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient. Any references to historical price movements or levels is informational based on our analysis and we do not represent or warranty that any such movements or levels are likely to reoccur in the future. While the information contained herein was obtained from sources believed to be reliable, author does not guarantee its accuracy or completeness, nor does author assume any liability for any direct, indirect or consequential loss that may result from the reliance by any person upon any such information or opinions.

Futures, Options on Futures, Foreign Exchange and other leveraged products involves significant risk of loss and is not suitable for all investors. Losses can exceed your deposits. Increasing leverage increases risk. Spot Gold and Silver contracts are not subject to regulation under the U.S. Commodity Exchange Act. Contracts for Difference (CFDs) are not available for US residents. Before deciding to trade forex and commodity futures, you should carefully consider your financial objectives, level of experience and risk appetite. Any opinions, news, research, analyses, prices or other information contained herein is intended as general information about the subject matter covered and is provided with the understanding that we do not provide any investment, legal, or tax advice. You should consult with appropriate counsel or other advisors on all investment, legal, or tax matters. References to or GAIN Capital refer to GAIN Capital Holdings Inc. and its subsidiaries. Please read Characteristics and Risks of Standardized Options.

Open an Account